Maria I. Roncero-Gomez

Toledo, CM, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica

Published: March 10, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 13, 2025

Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience.

Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience.

Journal: Transplantation and cellular therapy

Published: December 10, 2024

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Journal: Cancer

Published: August 07, 2024

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Journal: Haematologica

Published: January 16, 2023

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Journal: Blood advances

Published: May 21, 2021

Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.

Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.

Journal: Annals of hematology

Published: March 12, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026